Donald Trump’s electoral victory has shaken the market, mostly in a good way. The S&P 500 gained 5% in the first two days ...
Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist ...
With a market cap of $161.3 billion, New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. Known ...
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
Fiera Capital Corp trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission ...
Pfizer Inc.’s stock was unable to hold its early gains Tuesday and fell 2.4% after the company blew past estimates for the third quarter and raised its full-year guidance. The New York-based ...
Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Pfizer (PFE – Research Report) today. The company’s shares ...
Taking full advantage of the stock market and investing with confidence ... the most attractive and most discounted stocks. New York-based Pfizer markets a wide range of drugs and vaccines.
Pfizer's non-COVID product revenues surged 14% operationally last quarter. The oncology business delivered exceptional ...
The stock was down 1.3% at 3:21 p.m. in New York. Pfizer’s shares have shed more than half their value since peaking in December 2021. Since then, Bourla has embarked on a $70 billion string of ...